Becton Dickinson (BDX) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Becton Dickinson (BDX)

175.93

-1.14 (0.64%)

as of Aug 7, 2026, 4:52:42 pm Market Open.

131 watching

Investor Insights

Aug 7, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

Becton Dickinson (BDX-N) has undergone significant structural changes recently, including the spin-off of its life sciences business, which is now merged with WAT. This strategic shift positions BDX as a dedicated medical technology company, aiming to focus on higher-growth and higher-margin sectors. While the company's previous earnings per share (EPS) target for 2026 was $15, it has now adjusted this figure to $12.50. However, BDX's operating margin expectations have improved significantly, increasing from 21% to 25%. With the stock currently trading at a relatively cheap 14 times earnings, analysts remain cautious but optimistic, indicated by a price target of $200.00, describing the company as a wait-and-see opportunity due to the new risks associated with these changes.

Consensus

Cautious

Valuation

Undervalued

Similar

Medtronic,MDT

BUY

Manufactures medical devices. Looking for it to earn about $5.50 next year. Very steady, highly predictable.

BUY

Just recently purchased this. Has good revision and good valuation in the healthcare space. Products include syringes, monitors, catheters, etc. which healthcare services are in constant need of. Good growth and demand even when everything else is weak. Have some concerns on foreign exchange and margin issues because of increase in costs of raw materials. Expecting about 10% earnings growth in 2009, which is a great earnings profile.

BUY

If you go to a hospital in the US and look around, everywhere you go you see their products. There is a lot of concern that hospitals are not going to be able to spend the money that they have in the past so the stock has come down a long ways.

TOP PICK

Hospital supplies such as syringes, tests of blood supplies, etc. Off the radar on healthcare reform and pricing reform. Well diversified geographically with about 65% outside the US. Trading at 14 X earnings and looking at 12% growth.

TOP PICK

Hospital supplies. 16-18% growth in earnings over the last 10 years and expected to do the same in the next 5. Not expected to be impacted by the health care costs in the US. Strong balance sheet.

BUY

Hospital supply company as well as doing a lot of diagnostics testing. Had disappointing performance in the near term, but she likes it longer term. Growing at 18% to 17% with 60% to 70% of its profits outside of North America.

BUY

Great international company.

BUY

Medical supplies. Long time favourite. Unlike big pharma, has been delivering in terms of earnings 1st quarter was up almost 18%, well above expectations. Should continue to generate great returns, probably in the 10% to 12% range. Great international exposure.

HOLD

A leader in medical supplies with the main product being needles. Great stock and great company but right now, the valuation is not there.

PAST TOP PICK

(A Top Pick Mar 14/07. Up 15% including dividends.) Hospital supplies. Great company, but not well followed or well known. Well diversified with 60% revenues outside of North America. Good R&D. Trades at about 18X earnings. Still a Buy.

PAST TOP PICK

(A Top Pick March 14/07. Up 14.8 %.) Medical imaging. Under the radar in the healthcare sector. Market leader globally on diabetes products. Not expensive. Still a Buy.

BUY

A hospital supply manufacturer. Very solid, 15% plus earnings growth. Continue to like it. Will continue to deliver in a low tech safe way.

PAST TOP PICK

(A Top Pick Aug 21/06. Up 14.5%.) Medical supplies. A low-tech way of playing the increased demand for health care.

TOP PICK

A play on baby boom generation needing more medical care. Provides syringes, needles and hospital supplies. Strong presence in the diabetic sector. Makes about 23% ROE.

TOP PICK

A hospital supply company. Generally likes the demographic play of healthcare and this is a kind of low-tech way of playing it. The company also has a very strong diabetes section which is a big growth area in the US. Good dividend.

Showing 76 to 90 of 92 entries

Most Recent Experts

Rebecca Teltscher

Newhaven Asset Management

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Jim Cramer - Mad Money

CNBC

Jerome Hass

Lightwater Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Becton Dickinson (BDX)